Stephen J Richards

Summary

Country: UK

Publications

  1. ncbi request reprint The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory
    Stephen J Richards
    Department of Haematology, Haematological Malignancy Diagnostic Service, The Algernon Firth Building, Leeds General Infirmary, Leeds LS1 3EX, United Kingdom
    Clin Lab Med 27:577-90, vii. 2007
  2. ncbi request reprint Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, Department of Haematology, Leeds Teaching Hospitals NHS Trust, The Algernon Firth Building, Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom
    Cytometry B Clin Cytom 72:291-8. 2007
  3. ncbi request reprint Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence
    Matthew J Cullen
    Cancer Genet Cytogenet 148:176-7. 2004
  4. doi request reprint Immunophenotypic analysis of PNH cells
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, Leeds, United Kingdom
    Curr Protoc Cytom . 2002
  5. doi request reprint Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, St James s University Hospital, Leeds LS9 7TF, United Kingdom
    Cytometry B Clin Cytom 76:47-55. 2009
  6. ncbi request reprint Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom
    Blood 106:2559-65. 2005
  7. ncbi request reprint Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, Haematological Malignancy Diagnostic Service, Leeds General Infirmary, United Kingdom
    Blood 103:2027-31. 2004
  8. doi request reprint Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
    Anita Hill
    Department of Haematology, St James s Institute of Oncology, Leeds
    Br J Haematol 149:414-25. 2010
  9. doi request reprint Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, United Kingdom
    N Engl J Med 359:575-83. 2008
  10. ncbi request reprint Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, UK
    Br J Haematol 137:181-92. 2007

Collaborators

Detail Information

Publications18

  1. ncbi request reprint The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory
    Stephen J Richards
    Department of Haematology, Haematological Malignancy Diagnostic Service, The Algernon Firth Building, Leeds General Infirmary, Leeds LS1 3EX, United Kingdom
    Clin Lab Med 27:577-90, vii. 2007
    ..As with all rare diseases, internal and external quality assurance is essential for good laboratory practice and to fulfill the requirements of national laboratory accreditation schemes...
  2. ncbi request reprint Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, Department of Haematology, Leeds Teaching Hospitals NHS Trust, The Algernon Firth Building, Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom
    Cytometry B Clin Cytom 72:291-8. 2007
    ..In both these developments, flow cytometry played a critical role. In the first instance, in monitoring direct response to a new therapeutic agent; second, in demonstrating the phenotypic/genotypic link in a new form of GPI deficiency...
  3. ncbi request reprint Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence
    Matthew J Cullen
    Cancer Genet Cytogenet 148:176-7. 2004
  4. doi request reprint Immunophenotypic analysis of PNH cells
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, Leeds, United Kingdom
    Curr Protoc Cytom . 2002
    ....
  5. doi request reprint Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, St James s University Hospital, Leeds LS9 7TF, United Kingdom
    Cytometry B Clin Cytom 76:47-55. 2009
    ..Currently, no external quality assessment (EQA) programme or reference material is available for whole-blood PNH testing (red cells and leucocytes) by flow cytometry...
  6. ncbi request reprint Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom
    Blood 106:2559-65. 2005
    ..Eculizumab continued to be safe and well tolerated, and all patients completed the study. The close relationship between sustained terminal complement inhibition, hemolysis, and symptoms was demonstrated...
  7. ncbi request reprint Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, Haematological Malignancy Diagnostic Service, Leeds General Infirmary, United Kingdom
    Blood 103:2027-31. 2004
    ..If validated in prospective studies, blood monitoring at 2 and 4 weeks may be used to optimize therapy...
  8. doi request reprint Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
    Anita Hill
    Department of Haematology, St James s Institute of Oncology, Leeds
    Br J Haematol 149:414-25. 2010
    ..These data demonstrated that intravascular haemolysis in PNH produces a state of NO catabolism leading to signs of PH, including elevated NT pro-BNP and dyspnoea that are significantly improved by treatment with eculizumab...
  9. doi request reprint Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, United Kingdom
    N Engl J Med 359:575-83. 2008
    ..Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL...
  10. ncbi request reprint Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, UK
    Br J Haematol 137:181-92. 2007
    ....
  11. ncbi request reprint Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy
    Anita Hill
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals National Health Service Trust, Algernon Firth Building, Great George Street, Leeds, United Kingdom, LS1 3EX
    Blood 107:2131-7. 2006
    ..Thus, rhCD59-P corrects the CD59 deficiency in vitro and can bind to erythrocytes in an in vivo murine model, protecting the cells from the activity of human complement, and represents a potential therapeutic strategy in PNH...
  12. ncbi request reprint Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Department of Haematology, Leeds Teaching Hospitals National Health Science Trust, Leeds, United Kingdom
    N Engl J Med 350:552-9. 2004
    ..We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH...
  13. doi request reprint Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function
    Anita Hill
    Department of Haematology, St James s Institute of Oncology, Leeds, UK
    Br J Haematol 158:409-14. 2012
    ..Together, these data suggest a high prevalence of haemolysis-associated NO scavenging, Doppler-estimated systolic pulmonary hypertension, and depressed right ventricular function in patients with PNH...
  14. pmc Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
    Anita Hill
    1Department of Haematology, St James University Hospital, Leeds, UK
    Haematologica 95:567-73. 2010
    ..This may be due to C3-mediated clearance of paroxysmal nocturnal hemoglobinuria red blood cells through the reticuloendothelial system...
  15. ncbi request reprint The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model
    Claire Hall
    Haematological Malignancy Diagnostic Service, Leeds General Infirmary, Leeds, UK
    Acta Haematol 108:219-30. 2002
    ..Gene therapy remains a tantalising possibility, although a greater understanding of the pathophysiology of PNH is required, as well as advances in gene therapy techniques, before such an approach can be seriously considered...
  16. doi request reprint Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
    Richard J Kelly
    Department of Haematology, Leeds Teaching Hospitals, Leeds, UK
    Blood 117:6786-92. 2011
    ..001). Eculizumab dramatically alters the natural course of PNH, reducing symptoms and disease complications as well as improving survival to a similar level to that of the general population...
  17. ncbi request reprint Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, Academic Unit of Haematology and Oncology, Algernon Firth Building, University of Leeds, United Kingdom
    Blood 100:635-9. 2002
    ..8%-6.6%) of IgH somatic hypermutation. The monoclonal CLL phenotype cells present in otherwise healthy individuals may represent a very early stage of indolent CLL and should be useful in elucidating the mechanisms of leukemogenesis...
  18. ncbi request reprint Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, University of Leeds, HMDS, West Yorkshire, Surrey, United Kingdom
    Blood 100:2289-90. 2002
    ..The detection of CLL-phenotype cells provides a surrogate marker of carrier status, potentially facilitating gene identification through mapping in families and direct analysis of isolated CLL-phenotype cells...